Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer.
BACKGROUND
Circulation of cancer cells in the blood is a mandatory step for metastasis, but circulating tumor cells (CTC) have a low metastatic efficiency in preclinical animal models. In this prospective study, we reported the clinical outcome of nonmetastatic breast cancer patients according to CTC detection.


METHODS
In 115 nonmetastatic patients diagnosed with large operable or locally advanced breast cancer, we prospectively detected CTC using the CellSearch system before and after neoadjuvant chemotherapy in a phase II trial (REMAGUS02).


RESULTS
At baseline, 23% of patients were CTC positive, but only 10% had >1 CTC/7.5 ml of blood. After a median follow-up of 36 months, CTC detection before chemotherapy was an independent prognostic factor for both distant metastasis-free survival [DMFS; P = 0.01, relative risk (RR) = 5.0, 95% confidence interval (CI) 1.4-17] and overall survival (OS; P = 0.007, RR = 9, 95% CI 1.8-45). CTC detection after chemotherapy was of less significance (P = 0.07 and 0.09, respectively). Moreover, CTC detection showed interesting characteristics as an individual predictive test for metastatic relapses (sensibility 55%, specificity 81%, and global accuracy 77%).


CONCLUSIONS
Detection of > or =1 CTC/7.5 ml before neoadjuvant chemotherapy can accurately predict OS. Our findings may change the clinical management of nonmetastatic breast cancer and indicate that the metastatic efficiency of CTC could be higher than previously reported.
CirCe laboratory, Institut Curie, Paris; Department of Medical Oncology, Institut Curie, Paris.
F-C
FC
Bidard
CirCe laboratory, Institut Curie, Paris; Hematology laboratory, Institut Curie, Paris.
C
C
Mathiot
Department of Medical Oncology, Institut Gustave Roussy, Villejuif.
S
S
Delaloge
Department of Medical Oncology, Centre René Huguenin, Saint Cloud.
E
E
Brain
Department of Medical Oncology, Hôpital Saint Louis, Paris.
S
S
Giachetti
CirCe laboratory, Institut Curie, Paris; Pharmacology laboratory, Institut Curie, Paris.
P
P
de Cremoux
Department of Medical Oncology, Hôpital Saint Louis, Paris.
M
M
Marty
CirCe laboratory, Institut Curie, Paris; Department of Medical Oncology, Institut Curie, Paris; University Paris Descartes, Paris, France. Electronic address: jean-yves.pierga@curie.net.
J-Y
JY
Pierga
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology*; D002277:Carcinoma / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology*; D000068579:Celecoxib; D002469:Cell Separation; D003520:Cyclophosphamide / Q000008:administration & dosage; D000077143:Docetaxel; D055088:Early Detection of Cancer / Q000379:methods*; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009362:Neoplasm Metastasis; D009360:Neoplastic Cells, Circulating / Q000473:pathology*; D011720:Pyrazoles / Q000008:administration & dosage; D013449:Sulfonamides / Q000008:administration & dosage; D016019:Survival Analysis; D043823:Taxoids / Q000008:administration & dosage; D013997:Time Factors; D000068878:Trastuzumab; D055815:Young Adult
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D011720:Pyrazoles; D013449:Sulfonamides; D043823:Taxoids; D000077143:Docetaxel; D015251:Epirubicin; D003520:Cyclophosphamide; D000068579:Celecoxib; D000068878:Trastuzumab